Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal of all fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and cancer are increasingly recognised, including dysfunctional pan-PI3 kinase (PI3K) signalling as a driver of aberrant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorax
Hauptverfasser: Mercer, Paul F, Woodcock, Hannah V, Eley, Jessica D, Platé, Manuela, Sulikowski, Michal G, Durrenberger, Pascal F, Franklin, Linda, Nanthakumar, Carmel B, Man, Yim, Genovese, Federica, McAnulty, Robin J, Yang, Shuying, Maher, Toby M, Nicholson, Andrew G, Blanchard, Andy D, Marshall, Richard P, Lukey, Pauline T, Chambers, Rachel C
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2016
Schlagworte:
Interstitial Lung Disease
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4975851/
https://ncbi.nlm.nih.gov/pubmed/27103349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2015-207429
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge